Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours

Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations

METNET: A phase II trial of metformin in patients with well differentiated neuroendocrine tumours

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer